Market Overview:
The global pharmacodynamic biomarker testing market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for personalized medicine, and technological advancements in pharmacodynamic biomarker testing methods. Based on type, the global pharmacodynamic biomarker testing market is segmented into LC-MS and MS. The LC-MS segment is expected to grow at a higher CAGR than the MS segment during the forecast period from 2018 to 2030. This growth can be attributed to the increasing demand for high-throughput screening methods for drug discovery and development processes. Based on application, the global pharmacodynamic biomarker testing market is divided into hospital laboratories, diagnostic centers, and others (academic research institutes and contract research organizations). The hospital laboratories segment dominates this market owing to rising demand for early diagnosis of chronic diseases among patients admitted in hospitals.
Product Definition:
Pharmacodynamic biomarkers are measurable indicators of the pharmacodynamic effects of a drug. Pharmacodynamic biomarker testing can help to identify which patients are likely to respond to a particular drug, and can also help to assess the risk of adverse events. The importance of pharmacodynamic biomarker testing lies in its ability to improve patient care by helping clinicians select the best drug for each individual patient and by providing information on how well a drug is working.
LC-MS:
The pharmacodynamic biomarker testing market is expected to grow at a lucrative rate during the forecast period. The factors that propel its growth include increasing prevalence of chronic diseases such as cardiovascular, renal, and liver disorders along with rising geriatric population base.
Chronic diseases are progressive in nature and there is no permanent cure for them.
MS:
The global market for pharmacodynamic biomarker testing was valued at USD 2.5 billion in 2016 and is expected to grow at a CAGR of XX% during the forecast period. Increasing prevalence of multiple sclerosis, rising R&D investments by pharmaceutical companies, growing demand for personalized medicines are some factors driving the growth of this market globally.
Application Insights:
The hospital segment dominated the market in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to factors such as increasing prevalence of chronic diseases, growing geriatric population, and rising number of hospital admissions. Moreover, an increase in healthcare spending by governments as well as private organizations is likely to fuel industry growth during the forecast period.
Pharmacodynamic biomarker testing has various applications including disease diagnosis, drug development & toxicity screening in clinical research settings among others. The other application segment includes pharmacogenomics and personalized medicine which involves identification of genetic markers related to drug response that guides therapeutic decisions for patients with specific genotypes/haplotypes.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of new technologies and increasing healthcare expenditure in this region. Moreover, growing target population base coupled with rising prevalence of chronic diseases is expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure and rising awareness about biomarker testing among patients & physicians. Furthermore, an increase in per capita income will enable more people access health insurance which will further boost regional demand for biomarkers tests during the forecast period.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases such as cancer, cardiovascular disease, diabetes, and respiratory disorders account for more than 60% of all deaths worldwide. This is expected to drive the demand for pharmacodynamic biomarker testing in the coming years.
- Growing demand for personalized medicine: A major trend in modern medicine is personalized or precision medicine, which involves tailoring treatments to individual patients based on their genetic makeup or other biomarkers. Pharmacodynamic biomarkers play a key role in personalizing treatment by helping to determine how a patient will respond to a particular drug therapy. As such, their use is growing rapidly and is expected to continue doing so in the future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pharmacodynamic Biomarker Testing Market Research Report
By Type
LC-MS, MS
By Application
Hospital, Diagnostic Center, Others
By Companies
Almac, ACM Global Laboratories, Charles River, Agilent, Sygnature Discovery, Myriad RBM, AstraZeneca, BioAgilytix Labs, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Pharmacodynamic Biomarker Testing Market Report Segments:
The global Pharmacodynamic Biomarker Testing market is segmented on the basis of:
Types
LC-MS, MS
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Diagnostic Center, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Almac
- ACM Global Laboratories
- Charles River
- Agilent
- Sygnature Discovery
- Myriad RBM
- AstraZeneca
- BioAgilytix Labs
- Merck
Highlights of The Pharmacodynamic Biomarker Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- LC-MS
- MS
- By Application:
- Hospital
- Diagnostic Center
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pharmacodynamic Biomarker Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pharmacodynamic biomarker testing is a type of laboratory testing that uses pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers to identify the effects of a drug on the body. Pharmacokinetic biomarkers are markers that measure how much of a drug is being absorbed into the bloodstream after it is taken, while pharmacodynamic biomarkers are markers that measure how well the drug works in affecting specific body processes. Together, these two types of markers can help doctors determine which patients may be most likely to experience adverse effects from a particular medication and which patients may benefit most from taking it.
Some of the major companies in the pharmacodynamic biomarker testing market are Almac, ACM Global Laboratories, Charles River, Agilent, Sygnature Discovery, Myriad RBM, AstraZeneca, BioAgilytix Labs, Merck.
The pharmacodynamic biomarker testing market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pharmacodynamic Biomarker Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pharmacodynamic Biomarker Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pharmacodynamic Biomarker Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pharmacodynamic Biomarker Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pharmacodynamic Biomarker Testing Market Size & Forecast, 2018-2028
4.5.1 Pharmacodynamic Biomarker Testing Market Size and Y-o-Y Growth
4.5.2 Pharmacodynamic Biomarker Testing Market Absolute $ Opportunity
Chapter 5 Global Pharmacodynamic Biomarker Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pharmacodynamic Biomarker Testing Market Size Forecast by Type
5.2.1 LC-MS
5.2.2 MS
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pharmacodynamic Biomarker Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Diagnostic Center
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pharmacodynamic Biomarker Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pharmacodynamic Biomarker Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pharmacodynamic Biomarker Testing Analysis and Forecast
9.1 Introduction
9.2 North America Pharmacodynamic Biomarker Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pharmacodynamic Biomarker Testing Market Size Forecast by Type
9.6.1 LC-MS
9.6.2 MS
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Diagnostic Center
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pharmacodynamic Biomarker Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Pharmacodynamic Biomarker Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pharmacodynamic Biomarker Testing Market Size Forecast by Type
10.6.1 LC-MS
10.6.2 MS
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Diagnostic Center
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pharmacodynamic Biomarker Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pharmacodynamic Biomarker Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pharmacodynamic Biomarker Testing Market Size Forecast by Type
11.6.1 LC-MS
11.6.2 MS
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Diagnostic Center
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pharmacodynamic Biomarker Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Pharmacodynamic Biomarker Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pharmacodynamic Biomarker Testing Market Size Forecast by Type
12.6.1 LC-MS
12.6.2 MS
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Diagnostic Center
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pharmacodynamic Biomarker Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pharmacodynamic Biomarker Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pharmacodynamic Biomarker Testing Market Size Forecast by Type
13.6.1 LC-MS
13.6.2 MS
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pharmacodynamic Biomarker Testing Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Diagnostic Center
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pharmacodynamic Biomarker Testing Market: Competitive Dashboard
14.2 Global Pharmacodynamic Biomarker Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Almac
14.3.2 ACM Global Laboratories
14.3.3 Charles River
14.3.4 Agilent
14.3.5 Sygnature Discovery
14.3.6 Myriad RBM
14.3.7 AstraZeneca
14.3.8 BioAgilytix Labs
14.3.9 Merck
